KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of GPC1-Expressing Human Cancer” to NeoImmune Tech, Inc. (85 FR 18579). The technology to be licensed involves a potential therapy for “several cancer types with few treatment options – including uterine cervical cancer and pancreatic adenocarcinoma.” NeoImmune’s main product is a T cell amplifier that the company is exploring combining use with other compounds to treat a variety of types of cancers.

In addition to objecting to the exclusive license, KEI has stated that if the NIH proceeds with the license it should incorporate a series of provisions designed to safeguard the public interest in the invention and promote the policy objectives of the Public Health Service (PHS) Technology Transfer Manual.

A copy of KEI’s full comments regarding the exclusive license are available here (PDF updated April 28, 2020): KEI_UACT_Comments_Exclusive_License_NeoImmune_17April2020

(For more KEI comments on NIH licenses, see: